Novo Nordisk A/S (NYSE:NVO) Shares Sold by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 24.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,082 shares of the company's stock after selling 7,945 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Novo Nordisk A/S were worth $2,158,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Banco Bilbao Vizcaya Argentaria S.A. increased its position in shares of Novo Nordisk A/S by 2,249.3% during the fourth quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 99,470 shares of the company's stock worth $8,550,000 after purchasing an additional 95,236 shares in the last quarter. Coppell Advisory Solutions LLC boosted its position in shares of Novo Nordisk A/S by 31.6% during the 4th quarter. Coppell Advisory Solutions LLC now owns 28,048 shares of the company's stock worth $2,405,000 after purchasing an additional 6,732 shares in the last quarter. Oxford Wealth Group LLC grew its stake in shares of Novo Nordisk A/S by 20.1% during the 4th quarter. Oxford Wealth Group LLC now owns 14,989 shares of the company's stock worth $1,289,000 after purchasing an additional 2,506 shares during the period. MGO One Seven LLC lifted its stake in shares of Novo Nordisk A/S by 13.7% in the fourth quarter. MGO One Seven LLC now owns 20,066 shares of the company's stock valued at $1,726,000 after purchasing an additional 2,413 shares during the period. Finally, OneDigital Investment Advisors LLC increased its holdings in Novo Nordisk A/S by 18.2% in the fourth quarter. OneDigital Investment Advisors LLC now owns 42,342 shares of the company's stock valued at $3,642,000 after buying an additional 6,511 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 1.7 %

Shares of NYSE NVO traded up $1.14 during trading on Wednesday, hitting $66.30. 8,001,538 shares of the company traded hands, compared to its average volume of 6,154,501. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The firm has a market capitalization of $297.52 billion, a P/E ratio of 20.15, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average price of $72.84 and a 200-day moving average price of $88.85.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were given a $0.7874 dividend. The ex-dividend date of this dividend was Monday, March 31st. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is presently 49.54%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on NVO shares. Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating on the stock. Finally, Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has a consensus rating of "Hold" and an average price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.